Limitations of current therapies: Why do patients switch therapies?

European Neuropsychopharmacology

Volumn 18, Issue SUPPL. 3, 2008, Pages

  Falkai, Peter ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Antipsychotic agent; Schizophrenia drug therapy; Treatment outcome

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AKATHISIA; ARTICLE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COMORBIDITY; DISORDERS OF CARBOHYDRATE METABOLISM; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; HEALTH CARE COST; HUMAN; METABOLIC DISORDER; METHODOLOGY; NEUROLOGIC DISEASE; PARKINSONISM; PATIENT CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT OUTCOME; WEIGHT GAIN;

COST-BENEFIT ANALYSIS; HUMANS; PATIENT COMPLIANCE; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 50049112107     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.04.003     Document Type: Article

References (31)

1. Arseneault L., Moffitt T.E., Caspi A., Taylor P.J., and Silva P.A. Mental disorders and violence in a total birth cohort. Arch. Gen. Psychiatry 57 (2000) 979-986
2. Brown S. Excess mortality of schizophrenia. Br. J. Psychiatry 171 (1997) 502-508
3. Christensen A.F., Poulsen J., Nielsen C.T., Bork B., Christensen A., and Christensen M. Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study. Acta Psychiatr. Scand. 113 (2006) 148-153
4. Davis J.M., Chen N., and Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 60 (2003) 553-564
5. Eberhard J., Lindström E., and Levander S. Tardive dyskinesia and antipsychotics: a 5-year longitudinal study of frequency, correlates and course. Int. Clin. Psychopharmacol. 21 (2006) 35-42
6. Estroff S.E., Zimmer C., Lachicotte W.S., and Benoit J. The influence of social networks and social support on violence by persons with serious mental illness. Hosp. Community. Psychiatry 45 (1994) 669-679
7. Faries D., Ascher-Svanum H., Zhu B., Correll C., and Kane J. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. B.M.C. Psychiatry 5 (2005) 26 (May 27)
8. García-Cabeza I., Gómez J.-C., Sacristán J.A., Edgell E., and González de Chavez M. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO study). B.M.C. Psychiatry (2001) (1:7 Epub 2001 Dec 28)
9. Geddes J., Freemantle N., Harrison P., Bebbington P., and for the National Schizophrenia Guideline Development Group. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321 (2000) 1371-1376
10. Häfner H., and an der Heiden W. Course and outcome of schizophrenia. In: Hirsch S., and Weinberger D. (Eds). Schizophrenia (2003), Blackwell 101-141
11. Haro J.M., and Salvador-Carulla L. The SOHO (Schizophrenia Outpatients Health Outcome) study. Implications for the treatment of schizophrenia. C.N.S. Drugs 20 (2006) 293-301
12. Hennekens C.H., Hennekens A.R., Hollar D., and Casey D.E. Schizophrenia and increased risks of cardiovascular disease. Am. Heart J. 150 (2005) 1115-1121
13. Hofer A., Hummer M., Huber R., Kurz M., Walch T., and Fleischhacker W.W. Selection bias in clinical trials with antipsychotics. J. Clin. Psychopharmacol. 20 (2000) 699-702
14. Jones P.B., Barnes T.R.E., Davies L., Dunn G., Lloyd H., Hayhurst K.P., Murray R.M., Marwick A., and Lewis S.W. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Arch. Gen. Psychiatry 63 (2006) 1079-1087
15. Kane J., Honigfeld G., Singer J., and Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45 (1988) 789-796
16. Keefe R.S.E., Seidman L.J., and Christensen B.K. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am. J. Psychiatry 161 (2004) 985-995
17. Kerwin R., Millet B., Herman E., Banki C.M., Lublin H., Pans M., Hanssens L., L'italien G., McQuade R.D., and Beuzen J.N. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Eur. Psychiatr. 22 7 (Oct 2007) 433-443 (Epub 2007 Jun 7)
18. Krakowski M., Czobor P., and Chou J.C. Course of violence in patients with schizophrenia: relationship to clinical symptoms. Schizophr. Bull. 25 (1999) 505-517
19. Leucht S., Pitschel-Walz G., and Kissling A.W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res. 35 (1999) 51-68
20. Leucht S., Barnes T.R.E., Kissling W., Engel R.R., Correll C., and Kane J.M. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am. J. Psychiatry 160 (2003) 1209-1222
21. Leucht S., Wahlbeck K., Hamann J., and Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361 (2003) 1581-1589
22. Levander S., Eberhard J., and Lindström E. Clinical decision-making during five years of antipsychotic treatment. Acta Psychiatr. Scand., Suppl. 435 (2007) 17-26
23. Lieberman J.A. Comparative effectiveness of antipsychotic drugs. A commentary on Cost Utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS) and Clinical antipsychotic trials of intervention effectiveness (CATIE). Arch. Gen. Psychiatry 63 (2006) 1069-1071
24. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S.E., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K., and for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
25. Lindström E., Eberhard J., and Levander S. Five-year follow-up during antipsychotic treatment: efficacy, safety, functional and social outcome. Acta Psychiatr. Scand., Suppl. 435 (2007) 5-16
26. McEnvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S.E., Davis C.E., Severe J., Hsiao J.K., and for the CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 163 (2006) 600-610
27. Meltzer H.Y., and Bobo W.V. Interpreting the efficacy findings in the CATIE study: what clinicians should know. CNS Spectr. 11 suppl 7 (2006) 14-24
28. Stroup T.S., Lieberman J.A., McEvoy J.P., Swartz M.S., Davis S.M., Rosenbeck R.A., Perkins D.O., Keefe R.S.E., Davis C.E., Severe J., Hsiao J.K., and for the CATIE Investigators. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am. J. Psychiatry 163 (2006) 611-622
29. Tandon R., Carpenter W.T., and Davis J.M. First- and second-generation antipsychotics: learning from CUtLASS and CATIE. Arch. Gen. Psychiatry 64 (2007) 977-978
30. Tunis S.R., Stryer D.B., and Clacy C.M. Practical clinical trials. Increasing the value of clinical research for decision making in clinical and health policy. J.A.M.A. 209 (2003) 1624-1632
31. Wahlbeck K., Tuunainen A., Ahokas A., and Leucht S. Dropout rates in randomised antipsychotic drugs trials. Psychopharmacology (Berl.) 155 (2001) 230-233